11.01.12
Pronova BioPharma ASA and Takeda Pharmaceutical Co. Ltd. have received approval from the Japanese Ministry of Health, Labour and Welfare regarding a New Drug Application (NDA) for Lotriga granular capsule 2g (omega 3 acid ethyl esters 90) for the treatment of hyperlipidemia.
Lotriga, discovered by Pronova, is the omega 3-derived prescription drug containing highly concentrated and purified EPA and DHA. It is already on the market in 60 countries including the U.S. and Europe. In 2005, Takeda and Pronova entered into a license and supply agreement in which Takeda was granted the exclusive development and marketing right to this product in Japan. Lotriga will be the first prescription medicine in Japan that contains both EPA and DHA.
Lotriga, discovered by Pronova, is the omega 3-derived prescription drug containing highly concentrated and purified EPA and DHA. It is already on the market in 60 countries including the U.S. and Europe. In 2005, Takeda and Pronova entered into a license and supply agreement in which Takeda was granted the exclusive development and marketing right to this product in Japan. Lotriga will be the first prescription medicine in Japan that contains both EPA and DHA.